ASCO 2020: Neoadjuvant Ipilimumab and Nivolumab May Spare Therapeutic Lymph Node Dissection in Stage III Melanoma
Patients who could avoid therapeutic lymph node dissection had fewer surgery-related adverse event and better quality of life
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.